GNI Group Ltd is a Japan-based company engaged in pharmaceutical business and medical device business. The Company conducts global pharmaceutical research and development, manufacturing and distribution and biomaterials business. The Company operates in two business segments. The Pharmaceuticals segment conducts research and development, manufacturing, and sale of developed compounds, including ETUARY sold in the China market and Hydronidone (F351), which is in clinical trials. The main products also include other pharmaceuticals and reagents. The Medical Devices segment develops, manufactures, and sells medical devices such as biomaterials in the United States. This segment also includes medical device Designated Marketing Authorization Holder (DMAH) and In-Country Caretaker (ICC) services. The Company also conducts clinical and business development in the United States and conducts clinical development of F351 for Metabolic Dysfunction-Associated Steatohepatitis in the United States.

• Revenue in JPY (TTM)26.84bn
• Net income in JPY-4.41bn
• Incorporated2001
• Employees867.00

• Location
  GNI Group Ltd3F, Nihonbashi-Honcho YS Bldg2-2-2, Nihonbashi Hon-choCHUO-KU 103-0023JapanJPN
• Phone+81 362143600
• Fax+81 362143668
• Websitehttps://www.gnipharma.com/